28 Oct SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC) by SFA Therapeutics in NewsComments Read More... Read More
25 Oct SFA Therapeutics, Inc. To Present At The Microbiome R&D and Business Collaboration Forum by SFA Therapeutics in NewsComments Read More... Read More
25 Oct Student Analyzes Potential for a Startup’s Drugs by SFA Therapeutics in NewsComments Read More... Read More